weaken the way to play it, you buy gdx. >> wow. i'm melissa lee, thanks for watching. see you tomorrow at 5:00 for more "fast money." in the meantime, don't my mission is simple -- to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere. i promise to help you find it. "mad money" starts now. hey, i'm cramer! welcome to "mad money." welcome to cramerica. othepeople want to make friends. i'm just trying to save you money. my job isn't just to entertain but to teach it and put it all in context which you need right now. call me at 1-800-743-cnbc. or tweet me @jim cramer. sometimes we get days like today. where people just say, i have had it. i want out of here. >> sell sell sell sell. >> and that's pretty much the
instinct behind the sell-off. the nasdaq nosediving 1.62%. yet, people want to sell pretty much everything right now. particularly high growth. or maybe everything except what's being going down endlessly like oil where the stocks bounced. even as the price of crude failed to do so or herbalife that finally caught some lift. what's going on here? i think this market is changing the collaration. i think the vast majority of portfolio managers are fearful of buying the dips. it's too frightful to do so. let me explain. for the longest time ever since the market bottomed over six years ago if you decided to buy some down and out merchandise, you wanted to pick at some value or grab some growth stocks, they were bounced around by extraneous events, you did well.
in fact, the best strategy this year has been to wait for the stock of the company you like to come down to the bargain price and buy it. buying opportunities they have legion. all sorts of washington's toxic politics gave us some repeated dips in retrospect. they were fantastic times to snap up the stocks you wanted. i can't count the number of shutdowns, budget wrangling opportunities to buy high quality stocks at low prices. or how about the numerous fed rate shares. we heard that the fed was about to raise the rates. how ridiculous this parlor game became over the years wechl had four years, four years where important people shouldn't be maybe pundits, commentators, told us that the fed was about to raise rates and cause havoc for those who own stocks. they never did. each time we heard it, well, they were what do you say, amazing buy opportunities. maybe the fed is about to raise this time, but you know all those others are buy opportunities. then the incredible chances coming from overseas.
the on going russian/ukraine fracas and the cyprus crisis, the italian crisis, the greek crisis. and once again, the greek crisis. they were all moments where you got great prices to buy high quality american stocks. plain and simple. but something is different this time. it's got people thinking of passing on the dip. this time the decline is feeling more 2007 to 2009 like. buying stocks in the way down meant you were going to have to continue to buy stocks on the way down and you were going to lose money. i know you feel it, i do too. you can measure it. we had 60 new lows. if you bought them on the dips you were afly mated. we had whole sectors that proved illusory. coal, i get that. the coal companies are in the crosshairs of the president and the epa. no way you can beat that. that combination. then coal spilled over to copper and iron and the makers of the commodities are on the ropes. who knows when or even if they can bounce from that bruising if
you bought the dips in those you watch the stocks go lower still and then the commodity contagion spread to oil and gas and including the pipeline companies. when oil initially collapsed, and traded down to $43 not once but twice, lots of people bought the dips in the oil stocks and they were rewarded beyond their wildest dreams. oil bounced up to 60. stocks went soaring. it was breathtaking. including the most beaten up of names in the company's least prepared for the decline. here we are, back to 43. but the oil stocks are so far below the last time that crude was at the levels that they have become some of the most dangerous stocks out there. it started with just the heavily indebted companies, the smaller companies that borrowed money in order to exploit the different shales. they have been falling every day. then it's spread to the intermediates. multibillion dollar companies that had been market leaders they were fast growers. last week they got to the big
majors, world dutch, chevron, exxon. no way we'll have a nice recovery any time soon. forget for a moment that they bounced. core labs, a huge bounce. the declines have been stymied and they have wiped out hundreds of dollars in values. and sought out as many of you as safe haven, they have fallen apart. many down 40 or 50%. all the moves -- rails are next. by the fact that they had gotten involved in the oil transport and they carry coal. i can't believe how many times dip buying in this railroad group worked. not this time. then it spread to the industrials and the techs that had been so -- and the collapse of the stock market. i can tell you the host of companies that have been crushed by these, qualcomm, even yes, apple. the latter of the largest company in the world has been in a tail spin. it's obliterated the dip buyers.
only those who bought at the height of yesterday merrill induced decline, you know, the one i took my watch out at 112 and switched to my brylin, they have -- that's the only dip buyers made any money since the stock hit the peak. i want you to own apple. these stocks and the brethren like semiconductor winners, they're horrified. and now we have today where the buy on the dip strategy failed with some of the most reliable companies on earth. like the media stocks with the constant growth, so not subject to the super strong dollar and of course -- ♪ super freak >> and renewable earns stream. yesterday, disney got blasted and crushed again today. when they get slammed, stocks have been single best bouncers the ones that came back the fastest and the ones you reach for, this is too kissry for me.
i'm going to sell all the high fliers. so the sickness spread through the great growth stocks like the health care and the internets and the incredible breathtaking mid-morning pivot, some pirouettes. in the severity they took my breath away. and tesla missed and reported not so hot quarter. but then wouldn't show its hand about the future. stay tuned. even though commodities have come down, they have been spotty. the airlines, all of them, didn't matter how bad the airline or restaurant was. not this time. now add insalt to injury. other than the other stocks the only real leader, netflix up 2%. ouch. it's the slayer of all things media. what's good for netflix is good for netflix. nothing else. with this many new -- with this
new many lows, with the sole general netflix and no followers we have a stunning development. buying dips is the equivalent of falling off a tight rope without a trampoline. it's a symbol of complacency. have some cash on hand. don't fall in love with stocks as they dip and accept that you're not buying a dip. you're trying to catch a falling knife. unless you're a butcher block you'll have little to show for it, except bright red losses oozing from your portfolio. let's talk to a guy who knows what he's doing. let's go to cash in new jersey. cash? >> caller: booyah, jim. >> you be king, cash. >> caller: thanks for the great show, i love it. there's talk about a rare downstream verger where vm ware would buy out the 80% stake in vm ware or a complete buy jut by emc that's been talked about as
well. keep in mind emc owns 20% of vm ware. emc is going up and up. do you have any -- >> i know it's kind of a slow grower. vm ware has become the creature of the growth stock phenomenon, you buy it on dips and it doesn't rally anymore. be careful of both. doug in california? >> caller: thank you for taking my call. do you sell renos -- >> i got empanadas to die for. my empanadas, try them. >> caller: all right. three quick questions. mobi never gets a lot of press. they were down today. also, finally, on abmd, did you
crunch the numbers on their -- >> i love the abmd. let me give you my take on mobiley. get in line. all right, let's go to brandon in california. >> caller: booyah, mr. cramer, i'm brandon from los angeles. i need an nfl team right now. >> i think it would help espn. st. louis, i love you, but rams what can i tell you? >> caller: we'll take the niners with the new clean power plants, what is the portfolio stock like ss -- which is down 30%? >> solar city it goes up and down, trades with the first solar. that's the better play now. we'll do a major analysis of what went wrong for what went happened. i felt that this dip was different. i don't want you catching the falling knife.
cash, i think we just -- we spoke to cash, he was king. i say keep some on hand. "mad money" tonight. what is going on with allergen? it reported the first quarter and why did the stock sink? you want to hear that. i have the ceo. and the house of pain, a big loss for the group, don't miss my take. you have these products in your pantry right now, but can clorox help you clean up in this market? of course, it kills everything. maybe even bears, i don't know. i speak to the ceo just ahead. stick with cramer. fed noise. market dips. all just hours ahead of one of the most highly anticipated jobs report. cramer's final take coming up on last minute mad. >> announcer: don't miss a second of "mad money." follow @jimcramer on twitter. have a question? tweet cramer, #madtweets. send jim an e-mail to firstname.lastname@example.org or give us a
all right. what the heck just happened to allergen? remember, actavis changed the name after they purchased allergen. they reported a strong quarter, beating the wall street sales an earnings estimates, but they got slammed. closed down $17.17. of thises the company -- this was the company's first quarter after the acquisition in march. the first quarter since we learned last week that they're selling their drug business to teva. and they beat off the 348 basis and more than doubled thanks to the recent acquisitions. they have 70 products, yet they got hurt because management some people say put off updaying until september because of the prospective closing of the teva deal. seemed reasonable to me.
oh, the subpoena from the justice department is part of the probe into the generic drug prices weighed on the stock too. is this the long awaited pull back on a terrific stock that's been powering higher for years? even after today is up 7%? let's dig deeper with brent saunders saunders to find out more about the quarter and welcome back. thank you for coming in. we have some work to do and this stock was up immediately when people saw the quarter. then a couple of things happened. one was that the big hedge funds suddenly bolted out of growth. >> right. >> on the same day that you reported, second is that there was a filing that said there was a subpoena from the justice department, people panicked on that. walk us through the day of allergen. >> well, first of all, we had great day. executing in the face of
multiple deals and integrations. and i think i had proven year over year, quarter over quarter that our people are staying focused on the customers and the pipeline. that being said, the doj investigation really is a red herring. well, each one of the things are important and we disclosed it this morning the drug pricing in generics is first of all, we sold that business. second, the -- >> and teva is not going to back out because there's a justice -- >> no, it was disclosed to them. >> they knew. some people told me, oh, my god, teva just found out, that's untrue. >> that's correct. to be fair, the government in the u.s. has gotten used to drug prices and generics going down. but it's commodity business. they go up and down depending on supply and demand. this is a subpoena about three products where prices went up because of supply and demand. it will play out. but in the context of allergen it's not significant. >> where are we, how far along are we? >> we're pretty far along. in fact, in the u.s. which was the bulk of actavis and allergen, we are complete. around the world we were in the process of just starting the
legal entity consolidation in countries. and to be fair, thankfully we didn't get too far along because we sold most of the business to teva. instead of having to break apart something that was intermingled, it was never intermingled. it's easier to execute. >> i thought the analysts are focused on new drugs but you have a war chest. your company is inquisitive. this is not the company that will give you big dividends and slowed down. i figure you have the tax status. we are going to see something bold again from allergen, right? >> bold is our tag line. i encourage our employees to think and act boldly all the time. look, we practice what we preach. so history has been a good guide of us not being letting the grass grow under our feet for too long. we have been fairly inquisitive. we have done over $150 billion in deals a year alone. i hope we own some credibility that we'll deploy the capital,
in a creative manner. >> i'm glad you put it that way. i thought it didn't get you your due. aspirational numbers still out there in even without the generics? >> yeah, a great point. we have to lock at how we deploy the capital and how much time it take us to close the deal. to be able to reaffirm that target. that being said, we can buy our stock back and get back to $25 tomorrow but that may not be the right answer. >> i don't want you to do that. that's the pfizer way. don't pfizer us. >> i don't want to do it. but the point is if the street were looking for us to simply say we're committed to $25 i can show them a path to get there. but the right thing to do for our shareholders is to deploy the capital for a long term sustainable growth and keep the growth from the profile. >> i'm facetious about pfizer. that's great for a lot of people. it's the risk profile. i think you're suitable for younger people. we're not it for dividend. now, let's talk about the huge
drugs that also got lost in the shuffle of what happened today. >> they did. so we were in the early innings of launching the combination therapy for alzheimer's. this would be one pill once a day of the two only approved drugs classes for alzheimer's. really something the community, the caregiver, the physicians have been asking for for a long time. just recently fda approved. this is a medicare part "d" drug which means you need to get formulary access on the drugs that happens around the first of the year and we'll be in terrific shape for patients come january 1st. so we're building the launch to be ready in january 1st. and we're in a really strong position. >> okay. now, for david nicholson who has been around psychiatry said some things about the norex and depression. is it that good? >> look, it's early, but this is the most exciting thing that david has seen in his career. this is the first time we have
seen really strong proof of concept clinical research and repeated studies where we have break through therapy for depression. this is such a huge white space of unmet medical need. people go to ssi -- we have one today, we have a snri on the market today. but we need to break through. it can't be me too or slightly better drugs. this is game change. >> and some said he'd slash the r&d budget. that's brent saunders, this stock is misunderstood. the sellers got to it incorrectly. i know it's in my charitable trust i don't care. i'm telling you as it is. "mad money" is back after the break. coming up -- from cleaning products to personal care, clorox has just about everything for your home covered.
you know your denture can look but, when you eat tough food, the denture moves. oh no! this shouldn't happen. try fixodent plus adhesives. their superior hold helps your denture work more like natural teeth. and you can eat even tough food. fixodent. strong more like natural teeth. fixodent and forget it. is this the end of the world for the media stocks? no. but it's certainly the end of some of the higher valuations. however, i will say up front that disney which is the proximate cause of the sector wide decline remains the best
integrated media company in the universe. >> house of pleasure. >> i reiterate that when it comes to disney this weakness is indeed -- >> buy buy buy. >> in fact, many look back at the 104 intraday low price the stock hit today, it went it at $108.65 and will kick themselves for not pulling the trigger. with the whole group in free-fall why buy disney above the rest? because they're dominated by content which can be streamed and their channels can be dropped easily from your bundle. you can watch everything from viacom from a later date and that's why they're hardest hit. down 13%. but you can't stream espn, and that's the bread and butter cable offering. why does disney go down? because of the mechanics of the
stock market. not the mechanics of disney. stocks that have gigantic declines on day one tend to get hammered on day two. big institutions didn't finish cleaning house yet. i know they can come and go from the stock as they please, but a big institution needs help finding buyers for the stock. yes, the positions can be that massive and it's obvious that the brokers who are hunting for buyers yesterday could and find enough to take out the frantic sellers. they're selling stock that i they didn't finish selling yesterday. barring cat tree, i think they'll be cleaning up. the managers no longer believe disney is a growth stock. they want out of it. every share, no matter what price. i think that's plain dumb but i want you to put yourself into the sellers head.
they know disney stock is undergoing what's known as a rerating. meaning that disney and the rest of the media group aren't worth as much as they used to be because they have much less growth in the portfolio managers thought. no denying that if disney can't grow the subscribers, they have to cut prices to bring in more. or diversify away from cable. espn won't make as much money. remember, espn and cable, 50% of earnings. the issue i have with the sellers not -- it's not that bob iger doesn't see this or know it. come on, he's spent a huge amount of time and money building up the ten poles and the theme parks with "star wars" on the horizon, the company is in much better shape than time warner and viacom which depend on subscriber growth. so they can lose subscribers far more quickly than disney's espn will. once the big sellers do get finish and they do get finished
i think disney will be buying back stock hand over fist. if you take a super short term perspective, you're looking at it wrong. you need to evaluate it long term which are being ignored right now because of the line item cable subscribers. it was wrong to buy disney at $122 but down here you can pick up something. knowing they're diversifying away from cable and i think disney will succeed by this team next year, patience, please if you buy. remember with the stock of walt disney patience has always been rewarded. gabe in nevada. gabe. >> caller: hey, jim. that's my boy saying booyah. i watch your show every day religiously. >> that's fantastic. >> caller: what's your input on six flags? >> i don't want to slight cedar fair or fun. but we have had -- that stock -- fun is closer to the high. but we have had them on repeatedly. i have to tell you, i think both
those guys are what i call money. and six is real good. wow. both well run companies. how about joe in new jersey. >> caller: booyah, jim. joe in new jersey. i'm a big fan. i have a question about yahoo!. i know that the stock has recently been down and has not recovered. and they will be giving shareholders the spinoff of alibaba by the end of the year. are they a buy, sell or hold? be. >> i think they're a buy. i'll stick my neck out and say that the yahoo! japan has to be worth something. right now, valued at nothing. it's the end of the higher valuations for media stocks i get that. but it's not the end of the world. with patience disney is rewarded. much more "mad money" ahead, including my exclusive with the company that's been cleaning up for a century.
i have the ceo. then it's up more than 10% on health care for livestock and pets and a major activist to help it really work. don't miss my exclusive with the ceo of zoetis. and then the lightning round. stick with cramer. tomorrow -- kick off the trading day with "squawk on the street." live from post nine at the nyse. >> let me show you the inversion i'm doing. is there a camera on me? the numbers look better this way. >> it all starts at 9:00 a.m. eastern. ♪ every auto insurance policy has a number. but not every insurance company understands the life behind it.
10%. proctor is down 10%. kimberly-clark hasn't done much better and how is it that clorox soared while the rest of the group kind of languishes? has the brand become more attractive than the competition? is it because more people are buying out of hidden valley salad dressing, fresh step, burt's bee's i don't know, some of that. but clorox has a lot less international exposure than the others. and it's well imaged with fantastic marks and exciting r&d i want to talk about. they reported monday morning. they beat the numbers, company earning a buck 44. it was higher than anticipated revenues, good growth, much coming from the cleaning division. up 9%. meanwhile, the gross margins expanded year over year. this was a great quarter and hence why it's jumped below 112 up to 119.
and i know some would say, wow, hold on to the stock of a slow growing company that actually has a price -- 25 price to earnings multiple, are with ebeing risky? let's find out. let's check in with benno dorer, who's the new ceo. you have a better sense of where the company is headed. welcome. i had to say mr. dorer because i'm so used to donald canal. you're doing a fabulous job. i wanted to wish him well and what kind of hand did he give you? >> he gave me a great way. the way i like to talk about it, he gave me a beautiful train and that train is rolling down the right track and it's up to me to make it roll down faster and we're investing in the acceleration of growth, not just any growth, but good growth. >> well, let's talk about that. i saw some things i just loved. for example, i had been hoping that burt's bee's, you can put
some money behind that and get double digit. it's happening. >> burt's bee's has grown 11% last fiscal year. that's clearly one of the growth engines. there are three growth opportunities. first of all, we're driving awareness on the businesses that we have been in. for the first time, last fiscal year we did tv advertising and it's worked like gang busters. second, we are getting into new cat fo categori categories. we're getting into lip crayons and shimmers and we're downing down on that by getting into lipsticks. $800 million category where we can make a big difference and then third, we're in many countries and driving that. very optimistic about burt's bee's. >> burt's bee's fits their sweet spot. >> it does. you know, increasingly we're managing our business so we're investing in advertising and sales promotion online.
more than 30% of our advertising sales promotion dollars today are in digital and social media. in fact, today this morning, we have announced that we're forming a new strategic marketing relationship with google. google will help us send the right message to the right consumer at the right time. and we're very close to silicon valley. we can make that a competitive advantage for us. >> you know the people who own the media stocks are saying this is what's happening, clorox gets it. you have done some -- i remember when don when he would see there was flu and was able to get clorox to where it was by looking at twitter. >> yeah, today i can tell you that often our flu forecast is better than that of the weather channel. we're able to track social media. we find out where consumers talk about the flu. and then what we can do is we can send a display pallet to a
retailer close by so that people get the clorox disinfecting wipes or bleach they want. >> you mentioned the wipes. the growth here in wipes is rather extraordinary. i mean, what's happening. high single digits, what's going on? >> yeah, in fact, over the last quarter it's grown double digits and housewife penetration in the wipes category is still only 50%. so we have 50% to go. what's happening is that disinfecting and health and wellness is a relevant trend. but we are seeing a trend you mentioned millennials that we called cleaning in the flow. so what's happening is that people do no longer clean on their hands and knees on a saturday morning an take the morning off. today, what they want is those quick hits. those quick five minute hits. at the end of a meal, at the end of a day, at the end of a shower and that's where wipes come in. they're the preferred product form for them. we have tremendous innovation, the disinfecting wipes from
clorox with microscrubbers that have been successful. so we're growing household penetration. >> and i want to talk about innovation. i see innovation coming in in trash bags. >> yeah, trash bags has been a real star for us. over the last fiscal year and with the joint venture that we have together with our partners in proctor & gamble we have been able to churn out a real successful series of innovations. the last example being our glad odor shield with gain. we called consumers who love gain scent gain yaks and the -- >> i'm a gainyak. >> there you go. the flood trash cans with gain scent they have been successful. so we're gaining market share. >> another thing i do, my mom always said don't -- don't get clorox in your eyes. you solved it. you have the pod. >> well, that's another thing that we're doing, you have to go with the times.
we're launching bleach pack and crystals, which gives the disinfecting performance that they expect from clorox bleach in a much more convenient form. >> one last question. i know donald decided enough with venezuela. everyone is getting killed there except for you guys. a great move, isn't it? >> well, you know, for us it was the right thing to do. in the last fiscal year we were in, we lost $25 million on a business worth $77 million in sales. and we could not see a way to improve because we didn't get pricing from the government. so we're very strongly focused on doing what's right for the shareholders and exiting the company was the right thing to do. >> that's how you boost cash flow and the buy backs, that's clorox ceo benno dorer. "mad money" after the break.
>> caller: how's it going? i wanted to know what's your thoughts on the voya stock and why is there so little on the information -- >> i followed it. i remember when they rang the bell so maybe i'm closer to it than you are . i like the stock. mike in florida. >> caller: this is mike from key west, florida. i want to though your -- know your stocks on salesforce -- >> i think buying in this decline is a good not bad idea. john in florida, john? >> caller: yeah, hi, jim. down in florida. >> how you doing? >> caller: i'm doing okay. can you please give me your insight on dinah vaccinate? >> well, infectious disease
control is back, an is an important thing. i do like it, john. let's go to stewart in new york. >> caller: booyah, jim. from long island. >> oh, okay. you're up in there. >> caller: hey, jim, with the first of shear energy of liquefied natural gas expected to begin this year and viewed from the long term perspective, do we feel it an ideal time to buy -- >> carl icahn is become an activist. yeah, i'd want -- let me be a fly in the wall on that room. i think lng is good. i like the cpu and i think that's the preferred way to play this. that yield is 5.6% and gives you upside. let's go to roon in pennsylvania. >> caller: hey, jim.
[ indiscernible ]. >> which one i'm sorry? juneau, you can use the field bet on. highly speculative. if it works it's huge. if it doesn't stay right here. let's go to patty in south carolina. patty? >> caller: hey, cramer. it's a big boo-hoo hoo from me. what's up with box? >> i don't know. what's -- this one has proven to be a -- this is a battleground. erin levy runs a good company. and the fact that this company is only $1.6 billion, you know what i think the market is wrong on box. i will stick my neck out and say that. but that's what i think. alan in ohio. alan? >> caller: hello, jim cramer. >> what's up? >> caller: this is alan from the western basin of lake erie, home of the toledo mud hens, a big booyah to you. >> i like that.
what's up? >> caller: do you see brighter days in the future with the climate -- will the climate stay cloudy or is it time to cut the bait on ande? >> no, you can still fish there. the stock has been down down down down part of this kind of -- what i call this energy commodity short squeeze today. but no need to sell it. manny in michigan. >> caller: how's it going? >> good. how about you? >> caller: good. what is your opinion on monster -- >> everyone is selling this one. this is the one to buy. i'm saying, buy monster beverage. that, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. what are you working on? let me show you. okay. our thinkorswim trading platform aggregates all the options data you need in one place that lets you visualize that information
after brutal day like today i think it's worst circle back to companies who have reported strong results and won't be impacted by vicissitudes of economies around the world or the federal reserve. take zoetis, maker of vaccines for livestocks and pets. it's up 10% since we spoke to the ceo last september. the stock didn't really react much. the company drive delivered a 5%
earning speed and management raised the earnings forecast. yet, right now the stock's actually trading nickels and dimes below where it was when the company reported. here's a company getting a lot of new drug approvals, cutting costs and just exited venezuela which we know has been a positive for every company that has done that. let's not forget bill ackman owns a lot of it and they should do well. given the excellent quarter, i think it could be the same thing you buy on a day like today where it feels like everything is getting dinged. let's check in with juan ramon alaix the ceo of zoetis to hear more about the quarter. welcome back to "mad money." have a seat. >> thank you, jim. >> it seems ever since you got -- you got spun off from pfizer it's one thing after the other. cattle being very expensive. swine we have had flu.
we have had chicken illnesses. is this just endemic and zoetis is in the sweet spot or is something happened that made it so that the herds of animals that we have all -- we end up eating are -- they get sick too much? >> the animals get sick and we provide treatment. we make them better. >> i mean, it almost seems like that you're -- you're the crisis guy that everybody seems to call when it happens. >> yeah, but i think if there are outbreaks which is something that happened from time to time, happened in europe, in the u.s. and i think it's something that is part of the business. it's part of producers defining how to treat the animals and make the animals healthy. >> in other words it's not a one off thing. we should just expect as our -- as the world gets bigger and more people are added to -- that need to be fed this is just going to be a constant issue. the health of the livestock. >> the opportunity here, it's companies that will define the
issue and will bring solutions to mitigate the risk or the impact in their production. >> but it seems like in terms of developments and research and some of the great things that you're doing, it's companion animals. atopic dermatitis, for severe vomiting of cats and dogs. this has great growth given that people love their pets so much. >> also in livestock. >> right. >> what we introduced last year it was a -- it was a product for itchy dogs and now we announce another one which is a product that will be in the same area. dermatology and also will be in the -- it's a great demonstration of the innovation that we can bring. >> there's been a bit of a problem with the supply versus demand because of manufacturing
us shes. >> that's right. >> is that going to be past us by year's end? >> i think we're improving the process of manufacturing. we have the capacity. >> okay. >> and scale up of the manufacturing, it's presented a challenge. we have now fixed that and we expect that it will increase in terms of supply and in 2016 we'll be meeting all customers -- >> excellent. we had a delivering alpha conference here at cnbc and i asked bill ackman about the stake in zoetis. i have to give him enormous credit in a short period of time, they announced the major restructuring program. how are the interactions with your largest share holder? >> well, i think it's -- they're very positive. we have now representative on our board. that is good to have the perspective of important shareholder. in our discussion with our board. so i think it's going very well.
the discussions are excellent and the board and the management team is focused on performance, is focused on creating the value to our shareholder. >> ackman -- let's call him a constructive activist in terms of offering ideas to you. >> i think it's something in my opinion, that we have on the board. the discussions that we have in the board. they're showing that it's working well. >> one last question. there are -- there have been a lot of companies in the food chain, listen, we're taking the growth -- some of the artificial hormones out. you know, the genetically modified things. what's your view on that? you're about saving and curing illnesses. do you think the younger generation is worried about the genetically modified beef and chicken and are far off? >> my position is i respect any
kind of customer preferences. having said that, in my opinion, to date, to feed the world we need to use technology. >> okay. >> that is not only quality. but it's affordability. you can produce all organic, but in limited quantities and a price that many people will not be able to pay. >> you're an expert about this. i think you know more about animal health than anyone who's come on the sow. juan ramon alaix, ceo of zoetis. stick with cramer. can it make a dentist appointment when my teeth are ready? ♪ can it tell the doctor how long you have to wear this thing?
♪ can it tell the flight attendant to please not wake me this time? ♪ the answer is yes, it can. so, the question your customers are really asking is, can your business deliver? ♪balance transferot to othat's my game♪ bank you never heard of, that's my name♪ haa! thank you. uh, next. watch me make your interest rate... disappear. there's gotta be a better way to find the right card. whatever kind you're searching for, creditcards.com lets you compare hundreds of cards to find the one that's right for you. just search, compare, and apply at creditcards.com. ♪a one, a two, a three percent cash back♪
if an electric toothbrush was going to clean better than a manual. he said sure... but don't get just any one. get one inspired by dentists. with a round brush head. go pro with oral-b. oral-b's rounded brush head cups your teeth to break up plaque, and rotates to sweep it away. and oral-b delivers a clinically proven superior clean vs. sonicare diamond clean. my mouth feels super clean. oral-b. know you're getting a superior clean. i'm never going back to a manual brush.
weird mixture of complacency and negative. disney is down, that's an opportunity. allergen down huge after a terrific quarter. i don't know. how about apple holding in there, why? because the early read on china july sales they be they weren't so bad. i mean, look i don't want to be complacent. i know this market is tough. but i do want to point out that negativity the created a couple of buys and some things that were radically higher a few short days ago. and i kind of like that. but you know, don't be complacent. i like to say there's always a bull market somewhere. i promise to try to find it just for you right here on "mad money." i'm jim cramer. i will see you tomorrow. lemonis: tonight on "the profit,"
greenville, south carolina, is home to west end coffee... ...a regional roaster with great product... that's pretty awesome. ...but even better margins. -we sell it for how much? -john: $48. lemonis: that margin's killer. co-owners are living proof that you should never mix business with pleasure. john: [bleep] you're horrible at doing the right things until you're forced to do it. lemonis: i not only have to put the right process in place... you made a huge inventory mistake. ...i have to figure out a way for the owners to coexist. you're so busy fighting that you're not busy selling. if not, west end coffee will grind to a halt. all right. rookie mistake. my name is marcus lemonis, and i fix failing businesses.